Leveragen, Inc., a Boston-based biotechnology company advancing next-generation in vivo antibody discovery, announced today the issuance of a patent in Japan covering core innovations underlying its ...

In summer 2025, the SARS-CoV-2 JN.1 sublineage became dominant with more resistant variants, such as XFG, LP.8.1, and NB.1.8.1. COVID-19 mRNA boosters were therefore updated for the 2025–2026 season ...

The study offers one of the most detailed maps yet of how human antibody responses vary from person to person.

ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...

Creating a clear and well-defined bioanalytical methodology to quantify humoral and cellular immune responses is critical for ...

Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately $160 million of its common stock to date. Management believes these ...

ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...

Read more about Nanoparticle and AI-driven vaccines target broad protection against emerging threats on Devdiscourse ...

EAE-induced neuroinflammation. Using immuohistochemistry, flow cytometry, and single-cell RNAseq of doublets to interrogate cell-cell interactions, the authors provide solid evidence that macrophages, ...